Moberg Pharma regains rights to Emtrix® in certain EU markets

STOCKHOLM, November 10, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that
it has reached an agreement with its partner Meda to regain rights to Emtrix® in
certain EU markets where the nail product has not yet been launched, including
UK and Poland.
Moberg Pharma and Meda have agreed to amend their existing license and
distribution agreement so Moberg regains rights to the nail product in certain
EU markets. This includes UK, Poland, the Chech Republic and the Baltic
countries. The two companies maintain their partnership in the remaining
thirteen markets where the product has been launched under the brand names
Naloc® and Nalox® and reached a leading or top 3 position in the majority of
those markets.

“I am very pleased that we jointly agreed to focus our partnership on the
majority of markets where it has been successful. We are evaluating options to
launch by ourselves or through other distributors in the now released markets to
further leverage the potential of Emtrix® in Europe” said Peter Wolpert, CEO of
Moberg Pharma AB.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.00 am (CET) on November 10, 2015.

About Emtrix® and nail disease, www.emtrix.com
Emtrix is a topical treatment used to treat nail disease. Launched in late 2010,
it quickly became the market leader in the Nordics and recently also the best
-selling product in its category in the U.S. The international launch is under
way via a proprietary sales organization in the U.S. and ten partners that hold
rights for 50 markets, including the major EU markets, China, Turkey and Russia.
Emtrix is a prescription-free, over-the-counter product sold under the names
Kerasal Nail®, Naloc™/Nalox™ and Emtrix®. Safety and efficacy have been
demonstrated in several clinical studies including more than 600 patients.
Emtrix has a unique and rapid mechanism of action which brings visible
improvements within 2-4 weeks of treatment. Nail fungus is the most common nail
disease. The condition afflicts approximately 10 percent of the population and
is more common among the elderly. It is generally recognized that there is a
need for new efficacious and safe topical treatments.
For additional information, please contact:
Peter Wolpert, CEO, Phone: +46 (0)70 - 735 71 35, E-mail:
peter.wolpert@mobergpharma.se
Anna Ljung, CFO, Phone: +46 (0)70 – 766 60 30, Email: anna.ljung@mobergpharma.se
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal
Nail®, Balmex®, Domeboro®, Jointflex®, Vanquish®, and Fergon®. Kerasal
Nail®(Emtrix®or Nalox™ in certain markets) is a leading OTC treatment of nail
disorders in the U.S., Canada and several EU markets and is currently being
launched in Southeast Asia. The company is growing organically as well as
through acquisitions. Internal development programs focus on innovative drug
delivery of proven compounds and include two clinical stage assets, MOB-015
(onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has
offices in Stockholm and New Jersey and the company’s shares are listed on the
Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).